Low vemurafenib plasma exposure as a short-term predictive parameter of progression disease in metastatic BRAFV600 mutated melanoma

Trial Profile

Low vemurafenib plasma exposure as a short-term predictive parameter of progression disease in metastatic BRAFV600 mutated melanoma

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Jul 2015

At a glance

  • Drugs Vemurafenib (Primary)
  • Indications Malignant melanoma
  • Focus Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 21 Jul 2015 New trial record
    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top